Prostate cancer is the most commonly diagnosed cancer in the UK. But screening is not universal, and charities are divided over whether it should be extended. What do those living with the disease ...
The biopsy came back positive. It’s lung cancer.” Countless people in our community hear these words no one ever expects.
Profound Medical (PROF) announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic ...
First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA treatment ...
Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, ...
Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...
Market has emerged as a rapidly expanding segment within the oncology diagnostics and liquid biopsy landscape. Circulating Tumor Cells are cancerous cells that detach from primary or metastatic tumors ...
Detailed price information for Medicus Pharma Ltd (MDCX-Q) from The Globe and Mail including charting and trades.
An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following ...
Molecular profiling of tumors has been shown to improve risk stratification, and it may be useful for prostate cancer active surveillance.
Prostate cancer screening compares favourably to screening for breast cancer in identifying significant cancers, reducing mortality and avoiding unnecessary harms, says new research.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results